Device Choice Matters: High-delivery valved holding chambers (VHCs) significantly improve clinical scores (RDAI) and reduce hospitalization rates (NNT 3.3) in children with acute wheezing compared to low-delivery alternatives.
Neonatal Oxygenation: Automated FiO2 control is safe and reduces caregiver workload but does not significantly improve a composite outcome of death or major morbidity in extremely preterm infants.
Therapeutic Safety: Large-scale RCT evidence (PIPPA Tamariki) confirms that paracetamol use in the first year of life does not increase the risk of eczema or bronchiolitis compared to ibuprofen.
Metabolic Innovation: Inclisiran (siRNA) demonstrates sustained efficacy and safety in adolescents with heterozygous familial hypercholesterolemia, offering a simplified dosing regimen.
